Back to Search
Start Over
CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention
- Source :
- Pharmacogenomics. 18(12)
- Publication Year :
- 2017
-
Abstract
- Aim: Determine whether using CYP2C19 genotype to optimize antiplatelet therapy selection is cost effective over the initial 30 days and 1-year following percutaneous coronary intervention. Materials & methods: A cost–effectiveness analysis compared 30-day and 1-year outcomes and cost across three treatment strategies (universal clopidogrel, universal prasugrel, genotype-guided) in a hypothetical cohort. Results: Base-case scenario results at 30 days indicated that the incremental cost per major cardiovascular or bleeding event avoided for genotype-guided treatment was US$8525 and US$42,198 compared with universal clopidogrel and prasugrel, respectively. Probabilistic sensitivity analysis demonstrated that genotype-guided treatment was cost effective over 30 days and 1 year in 62 and 70% of simulations, respectively. Conclusion: Implementing a CYP2C19 genotype-guided approach to antiplatelet therapy could have a positive economic impact by preventing readmissions following percutaneous coronary intervention.
- Subjects :
- medicine.medical_specialty
Prasugrel
Ticlopidine
Genotype
Cost effectiveness
medicine.medical_treatment
Cost-Benefit Analysis
Hemorrhage
CYP2C19
030204 cardiovascular system & hematology
Drug Costs
03 medical and health sciences
0302 clinical medicine
Percutaneous Coronary Intervention
Genetics
medicine
Humans
030212 general & internal medicine
Acute Coronary Syndrome
Pharmacology
business.industry
Cyp2c19 genotype
Percutaneous coronary intervention
Cost-effectiveness analysis
Clopidogrel
Cytochrome P-450 CYP2C19
Cohort
Emergency medicine
Molecular Medicine
business
Prasugrel Hydrochloride
Platelet Aggregation Inhibitors
medicine.drug
Subjects
Details
- ISSN :
- 17448042
- Volume :
- 18
- Issue :
- 12
- Database :
- OpenAIRE
- Journal :
- Pharmacogenomics
- Accession number :
- edsair.doi.dedup.....bbb3795e18f15841153b413f5ec2c85c